Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa With Food (Within 30 Minutes After a Meal) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment With Pradaxa 150 mg b.i.d., 110 mg b.i.d., or 75 mg b.i.d. for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation (NVAF)

Next Previous
Trial Profile

A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa With Food (Within 30 Minutes After a Meal) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment With Pradaxa 150 mg b.i.d., 110 mg b.i.d., or 75 mg b.i.d. for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation (NVAF)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Pantoprazole
  • Indications Gastrointestinal disorders; Stroke; Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 01 Dec 2016 Primary endpoint (The Rate of Complete Effectiveness of Initial GIS Management Strategy) has not been met,according to the results published in the Cardiology and Therapy.
  • 01 Dec 2016 Results published in the Cardiology and Therapy
  • 06 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top